AstraZeneca says late-stage trials of its COVID-19 vaccine were ‘highly effective’ in preventing disease
Interim analysis of the COVID-19 vaccine candidate developed by the University of Oxford and manufacturer by AstraZeneca has shown up to 90% effectiveness at protecting against the disease in more than 11,000 participants from the United Kingdom and Brazil. A regimen involving a half dose followed a month later by a full dose was found to be 90% effective, while one involving two full doses a month apart was 62% effective. As noted in earlier COVID-19 DEW Reports, Moderna and Pfizer also reported effectiveness above 90% for their respective vaccine candidates, making AstraZeneca’s the third set of promising results in the past several weeks. The AstraZeneca vaccine candidate can be stored between 2-8 Celsius, while others in development require storage temperatures as low as -80 Celsius.
Published: November 23, 2020
CBC NewsRead Article